Palatin Technologies Provides Assessment of Impact of COVID-19 Pandemic on Business Operations
– Dry Eye Disease Phase 2 Study Remains on Track – Data Anticipated in 4Q20 – $89 Million in Cash at March 31, 2020 CRANBURY, N.J., April 30, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic …